An evaluation has been carried out of 13 commercial testosterone kits. The within-and between-assay imprecision was found to be unsatisfactory for some kits. Sensitivity and linearity were acceptable for all the kits but several showed concentration-dependent biases to the ALTM or GCMS values. The occurrence of anomalous results and changing performance characteristics of some of the direct kits is also presented.
Most of the plasma testosterone in men is secreted from the testes with only 5% being derived from the adrenals. In women about equal amounts are secreted by the ovaries and the adrenals. I The measurement of plasma testosterone in male serum is used predominantly for the investigation of hypogonadism and for monitoring replacement therapy. It is also used in the investigation of precocious puberty and in monitoring testicular response to HCG stirnulation.v : ' In women, plasma testosterone is used in the investigation of hyperandrogenisation and has been found to be of most help in cases of hirsutism which are of recent onset. Concentrations greater than 6·0 nmol/L are suggestive of an androgen-secreting adrenal or ovarian tumour.
The measurement of plasma testosterone has therefore, an established clinical role. Assays used for this determination must have a reliability sufficient to meet the clinical requirements. It is also desirable that results from different assays should agree closely so that changes of methodology, which may be brought about by various circumstances, do not complicate the interpretation of results. This study was carried out to examine the performance of commercial kits used for the measurement of total testosterone in plasma and their suitability for routine clinical investigations. Correspondence 
The evaluation
This has been carried out on 13 commercial kits following the recommendations of Percy-Robb et at. 4 The manufacturer and UK distributor of each kit are given in Table 1 . Eight kits were d . 5 examined as part of a DHSS-supporte project and are indicated in Table 1 . Intra-assay precision was determined from 20 replicates of five pools and between-assay precision from the replication of the same five pools in 12 separate assays. Accuracy was assessed by measuring the testosterone concentration in pools in which the content of this hormone had been determined by gas chromatography-mass spectrometry (GC-MS).6 The cross-reaction of each kit's antiserum with 10 physiologically relevant steroids was examined by the method of Abraham." Sensitivity (defined as the mass equivalent to two standard deviations from the zero binding count value), linearity, recovery and the possible interference of elevated levels of lipid, protein and haemoglobin were also studied. The stability of the kits was examined by measuring the same 17 samples on receipt of a kit and at the end of its shelf life.
A smaller evaluation was carried out on a further five kits of which only six kit packs were supplied. Intra-assay precision was determined from 10 replicates of three samples and between-assay precision from three samples in five assays. Sensitivity, linearity, and the crossreaction with androstenedione and 5adihydrostesterone were also studied. The first kit pack from each manufacturer was used to measure the testosterone concentration in clinical samples previously determined by the investigating laboratory's in-house method. This procedure highlighted any large bias a kit may exhibit which could make certain evaluation samples unmeasurable. It also familiarised the operator with the kit procedure.
Results
The packaging and labelling were examined for compliance with IFCC recommendations and, in the case of the Steranti kit, was found to be inadequate. The package label with this kit provided no caution regarding the presence of radioactive material and the package insert gave no guidelines or caution for the handling of radioactive substances. There was very little information on the performance characteristics of this kit. Packaging and labelling of all the other kits were found to be adequate.
Details of the methodology of each kit are given in Table 2 . Five kits involved ether extraction before radioimmunoassay thereby increasing the time required to perform the method. The antibody-coated tube technique of the Coat-a-Count kit obviates the need for centrifugation. The incubation time given is the minimum recommended time since some manufacturers indicate that the time may be increased to allow overnight incubations without any deleterious effects. It will be noticed that the direct methods, i.e. non-extraction methods, require smaller volumes of sample and usually the same volume is suitable for both male and female samples. Intra-assay and inter-assay variation is given for each kit in Table 3 . Most kits had an acceptable within-assay imprecision although the results of Biomerieux, Farmos (extraction). Serono and Steranti kits indicate that precision in the female range is likely to be poor. The between assay imprecision was considerably worse for some kits. As these analyses were carried out on the same reagent batch number, it is likely that the performance in a routine laboratory will probably be worse due to batch variation.
None of the kits showed inaccurate measurement of testosterone concentration in samples which were Iipaemic, haemolysed or contained elevated levels of protein and all showed good linearity when a sample from a male subject was sequentially diluted with a sample from a female subject. Dihydrotestosterone was the only steroid which gave a cross-reaction of more than 1·0% and therefore only the crossreaction of antisera with this steroid is given in Table 3 . Sensitivity is also given and shows that many kits are unsuitable for measuring the low levels of testosterone found in paediatric samples. Fig. 1 compares eight kit results with the GCMS and the all laboratory trimmed mean (ALTM)8 for seven male NEQAS samples. It can be seen that the RIA-MAT kit had a positive bias of 25% both to the GCMS and the ALTM in all samples. The Biomerieux kit was consistently slightly positively biased to the ALTM and the Steranti kit was consistently negatively biased to the GCMS results. The bias to GCMS and AL TM was less consistent for the other kits. GCMS values were only available on samples from men and these samples were not available for studying five of the kits. A comparison of all the kits has been achieved by comparing the percentage bias from the ALTM of certain NEQAS samples which is given in Fig. 2 . The Liquisol kit had a progressively increased bias with decreasing concentration. The Leeco kit had a consistently 8·9  18·3  8·5  16·5  5·0  12·3  10·1  12·3  3·3  7·0  3·0  6·9  2·7  6·5  4·3  24·7 14·4
large negative bias and the OPC and Farmos kits also showed a progressively increasing negative bias with increasing concentration. The testosterone concentration of the NEQAS sample with the lowest concentration was undetectable by the OPC kit «1·0 nrnol/L). The other kits were within ±20% of the ALTM at most concentrations with no change in the bias related to concentration. A comparison of kit results for NEQAS samples with the ALTM or GCMS values does not expose all the problems which may be encountered. A number of NEQAS participants reported high testosterone values obtained with one of the direct kits which were not confirmed by extraction methods either with or without chromatography. This promp- ted a more detailed study of the other kits and Table 4 shows discrepancies between an extraction assay and some of the direct commercial kits.
In addition to this, changes in reagent or adaptations to the method may lead to changes in the bias of a kit without any warning to the user. Fig. 3 shows the changing monthly bias to the AL TM of the Leeco kit used by three NEQAS participants.
When the same 17 samples were analysed on receipt of a kit and at the end of its shelf life a significant difference between the results on the two occasions was found for the Liquisol, RIA-MAT and Serono kits. The quality control samples indicated that the assays were in control.
Discussion
The details and performance of 13 commercial kits for the measurement of testosterone in plasma or serum have been presented. It should be noted that some manufacturers recommend a particular matrix. Packaging and labelling were adequate for all but the Steranti kit. Only half the manufacturers provided control sera or a quality control chart; without these a user does not know whether a kit is performing correctly.
The direct methods did not perform better than the extraction methods and so the advantage of the direct method is the exclusion of a lengthy and tedious extraction step. The coated tube technique of the OPC kit excluded the need for centrifugation making this kit, with its good precision and sensitivity, very attractive. However, the study highlights some problems which may arise. For instance the RIA-MAT kit was shown to have a consistently high bias at all concentrations and probably indicates a standardisation problem. The Liquisol kit, although discontinued, has been included since it demonstrates very clearly (Fig. 2 ) an increasing positive bias as the concentration decreases. Other kits, DPC and Farmos, showed an increasing negative bias with decreasing concentration. The phenomenon would result in a poor variability of bias on the NEQAS scheme.
Some kits appeared to show a consistent negative bias to the ALTM which could be explained by either greater specificity, incomplete recovery, or a standardisation problem.
The results in Table 4 indicate that some substance(s), presumably steroidal, in the serum of certain samples may lead to high results when using the direct methods. Since the incidence of such discrepancies may be only 1-3%, these anomalies are difficult to detect and may lead to inappropriate treatment of the patient. This deficiency in direct methods may explain why most laboratories measuring testosterone in blood continue to use an extraction method. The performance characteristics of a kit method may change dramatically (Fig. 3) over a period of time leading to inconvenience and unnecessary expense in trouble-shooting to the user laboratory. This highlights the need for good in-house quality control.
Although NEQAS does not detect the latter two problems readily, pooling of the experiences of participants with these kits has been invaluable in quickly exposing such anomalies and it falls to the NEQAS organiser to disseminate this information quickly.
